

# NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## Health Technology Evaluation

### Equality impact assessment – Scoping

#### Asfotase alfa for treating paediatric-onset hypophosphatasia (review of HST6) [ID3927]

The impact on equality has been assessed during this evaluation according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

The current eligibility criteria under the managed access scheme excludes some HPP (paediatric-onset) patients from accessing this technology, impacting equity and access to this technology. It is not clear whether these criteria will be applied should the technology receive a positive recommendation, therefore we seek further clarity from NICE in this regard.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

Asfotase alfa will be re-appraised within its licensed indication. .

3. Has any change to the draft scope been agreed to highlight potential equality issues?

No changes have been made

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the stakeholder list been made?

No additional stakeholders have been identified

**Approved by Associate Director (name):** Richard Diaz **Date:** 29 April 2022